FDA APPROVED
For the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy1


FDA APPROVED
For the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy1
Clearly
for Her
CIMZIA®—clearer skin that lasts,
so she can plan ahead1,18,19
Co-primary endpoints were PASI 75 and PGA 0/1. A majority of patients responded at Week 16, and responder rates were maintained to Week 48 with 200 mg every other week maintenance dosing. (N=1020. 113 female subjects treated with 200 mg Q2W)1,5,18,19
See the trialsCIMZIA has 6 approved indications1
Moderate to Severe Plaque Psoriasis in adults who are candidates for systemic therapy or phototherapy
Moderately to Severely Active Crohn’s Disease if response to conventional therapy is inadequate
Moderately to Severely Active Rheumatoid Arthritis
Active Psoriatic Arthritis
Active Ankylosing Spondylitis
Non-radiographic Axial Spondyloarthritis